secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001730430-26-000021
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr
------------------------------------------------------------------

- Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.
- Decision not due to any disagreement with the company on operations, policies, or practices.
- Will serve as consultant and special advisor to Science and Research Committee for up to 20 hours/month at $450/hour.
- Consulting agreement runs from May 15, 2026 to May 15, 2027, renewable by mutual agreement.
- Company reimburses reasonable pre-approved travel and out-of-pocket expenses for consulting services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000021/0001730430-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000021/knsa-20260430x8k.htm
  HTML page:      https://secwatch.observer/filing/0001730430-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer